|View printer-friendly version|
|PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
Other Events, Financial Statements and Exhibits
Item 8.01. Other Events
On December 18, 2014, PlasmaTech Biopharmaceuticals, Inc. (the "Company") issued a press release announcing the pricing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $0.01 per warrant. The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The shares and warrants will begin trading on The NASDAQ Capital Market on December 19, 2014 under the symbols "PTBI" and "PTBIW," respectively.
The gross proceeds to the Company from this offering are expected to be $14.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and warrants in the offering are being sold by the Company.
The offering is expected to close on December 24, 2014, subject to customary closing conditions. The Company has also granted the underwriter a 45-day option to purchase up to an additional 525,000 shares of common stock and/or 525,000 warrants to cover over-allotments, if any.
A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
99.1 Press release dated December 18, 2014, entitled "PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ"